Molecular targeted therapyImmune checkpoint inhibitorMutationSmall cell lung cancer (SCLC) is one of the major pathological types of lung cancer. Most of the patients with SCLC remain uncured with standard treatment consisting of platinum-based chemotherapy and have poor prognosis. The genomic ...
From 67%-75% of people who develop small cell lung cancer will have spread the SCLC outside of the lung to other parts of the body at the time of initial diagnosis. Small-cell lung cancer responds well to chemotherapy (using medications to kill cancer cells) and radiation therapy (using ...
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by an exceptionally high proliferative rate, strong predilection for early metastasis and poor prognosis. SCLC is strongly associated with exposure to tobacco carcinogens. Most patients have metastatic disease at dia...
Small cell lung cancer(SCLC) represents about 15% of all lung tumors, is extremely aggressive, is frequently associated withdistant metastases, and has the poorest prognosis of all lung neoplasms. The incidence is decreasing for unknown specific reasons; however, it may be related to the greater...
Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy foll... are predictors of prognosis in non-small celllung cancer patients treated with adjuvant chemotherapy fol-lowing surgery.Japanese Journal of Clin...
Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis. Most of the patients present with distant metastatic disease at the t
= fractions; IMRT = intensity modulated radiation therapy; KQs = key questions; LS = limited-stage; MRI = magnetic resonance imaging; OS = overall survival; PCI = prophylactic cranial irradiation; RT = radiation therapy; SBRT = stereotactic body radiation therapy; SCLC = small cell lung cancer...
Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.circulating tumor cellsprognosissmall-cell lung cancer... - 《Annals of Oncology》 被引量: 0发表: 2012年 Class III -...
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 Ann Oncol (2021), 10.1016/j.annonc.2021.01.071 Google Scholar 17 T.K. Owonikoko, K. Park, R. Govindan, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451 ...
In recent years, the five-year survival rate of patients with advanced stage non-small cell lung cancer (NSCLC) remains low despite recent advances in surgery, irradiation, chemotherapy, and targeted therapy. Immunotherapy which utilizes the immune system to control and eradicate cancer is a viable...